TY  - JOUR
A1  - Van Baelen, Anthony
A1  - Mottet, Nicolas
A1  - Spahn, Martin
A1  - Briganti, Alberto
A1  - Gontero, Paolo
A1  - Joniau, Steven
T1  - Sense and Nonsense of an Extended Pelvic Lymph Node Dissection in Prostate Cancer
JF  - Advances in Urology
N2  - Lymph node metastases associated with prostate cancer (PCa) has been shown to be a poor prognostic factor. The role of pelvic lymph node dissection (PLND) itself in relation to survival remains unclear, however. A Medline search was conducted to address this issue. The following conclusions were drawn. Only recently, improved survival due to completion of radical prostatectomy (RP) (compared to abandoning RP) in known or presumed lymph-node-positive patients has been shown. Lymph node sampling can only be considered representative if an adequate number of nodes is removed. While several authors have suggested that a therapeutic benefit in patients undergoing RP is not provided by PLND, the reliability of these studies is uncertain. Contrary to this, several studies have indicated the possibility of long-term survival even in the presence of limited lymph node metastases. The role and timing of initiation of adjuvant androgen deprivation therapy (ADT) in patients who have node-positive disease after RP is controversial. Recent studies suggest that delaying ADT may not adversely impact survival.
KW  - Prostatakrebs
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123990
VL  - 2012
IS  - 983058
ER  - 
TY  - JOUR
A1  - Schubert, Maria
A1  - Joniau, Steven
A1  - Gontero, Paolo
A1  - Kneitz, Susanne
A1  - Scholz, Claus-Jürgen
A1  - Kneitz, Burkhard
A1  - Briganti, Alberto
A1  - Karnes, R. Jeffery
A1  - Tombal, Bertrand
A1  - Walz, Jochen
A1  - Hsu, Chao-Yu
A1  - Marchioro, Giansilvio
A1  - Bader, Pia
A1  - Bangma, Chris
A1  - Frohneberg, Detlef
A1  - Graefen, Markus
A1  - Schröder, Fritz
A1  - van Cangh, Paul
A1  - van Poppel, Hein
A1  - Spahn, Martin
T1  - The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis
JF  - Advances in Urology
N2  - Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n=86 ) or no adjuvant ADT (group 2, n=86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5–10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.
KW  - prostate cancer
KW  - adjuvant hormonal treatment
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137712
VL  - 2012
ER  -